Results 31 to 40 of about 18,746 (183)
Current Research in Pharmacology and Drug Discovery, 2022 Alzheimer's Disease (AD) is characterized as a progressive neurodegenerative disease most commonly associated with memory deficits and cognitive decline.
Yasir Hasan Siddique +3 more
doaj +1 more source
Cognitive dysfunction and dementia in Parkinson's disease [PDF]
, 2004 Parkinson's disease (PD) is a slowly progressive neurodegenerative disorder mainly characterized by degeneration of dopaminergic neurons in the substantia nigra and the ventral tegmental area, in combination with a varying loss of central noradrenergic ...
Bosboom, JL +2 more
core +1 more source
Antimuscarinic delirium in a pediatric patient reversed with transdermal rivastigmine: A case report
JEM ReportsBackground: Antidotal treatment of antimuscarinic delirium (AMD) standardly involves parenteral administration of physostigmine. However, due to cessation of physostigmine production, administration of oral or transdermal rivastigmine may serve as a ...
Natalie E. Ebeling-Koning +5 more
doaj +1 more source
Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia [PDF]
Journal of Movement Disorders, 2015 Objective A recent study showed that rivastigmine and memantin improved behavioral and psychiatric symptoms of dementia (BPSD) in Alzheimer’s dementia. Furthermore, according to recent guidelines presented by the Movement Disorder Society, rivastigmine ...
Yoon-Sang Oh +2 more
doaj +1 more source
Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. [PDF]
, 2015 In Alzheimer disease, the gap between excellence of diagnostics and efficacy of therapy is wide. Despite sophisticated imaging and biochemical markers, the efficacy of available therapeutic options is limited.
Alessandro eStefani +9 more
core +3 more sources
Антибиотики и Химиотерапия, 2023 The basis for conducting bioequivalence studies is the determination of the bioavailability of the active substance of the drug at its place of action by establishing the concentration of the drug in biological fluids using sensitive analytical techniques.
M. S. Dolov +3 more
doaj +1 more source
Effect of Rivastigmine on Mobility of Patients with Higher-Level Gait Disorder: A Pilot Exploratory Study [PDF]
, 2014 Background: Higher-level gait disorder (HLGD) in older adults is characterized by postural instability, stepping dysrhythmicity, recurrent falls and progressive immobility. Cognitive impairments are frequently associated with HLGD. Objectives: The aim of
Balash, Yacov +6 more
core +2 more sources
Advanced Science, EarlyView.This study tests NeuroD1 AAV‐based gene therapy in a non‐human primate Alzheimer's disease model. The therapy prevents neuronal damage, inhibits hippocampal atrophy, and reduces neuroinflammation. It also repairs vascular and blood‐brain barrier damage, restores cerebrospinal fluid biomarkers, enhances hippocampal glucose metabolism, and improves ...
Zhouquan Jiang +21 more
wiley +1 more source
Tijdschrift voor Gerontologie en Geriatrie, 2023 Doel van onderzoek In Nederland zijn vanaf januari 2008 twee eenmaaldaags toe te dienen cholinesteraseremmers geregistreerd voor de symptomatische behandeling van milde tot matige ziekte van Alzheimer, namelijk oraal galantamine en rivastigmine ...
C.J. Wouters +3 more
doaj +1 more source
Frontiers in Pharmacology, 2020 BackgroundAcetylcholinesterase inhibitors (AChE-I) are recommended for the treatment of cognitive symptoms but also of behavioral and psychological symptoms in dementia.
Marion Ortner +12 more
doaj +1 more source